Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jul
13
Today In Oncology
Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy
Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer
Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
Emergency Hospital Admission Accounts for 40 of Ovarian Cancer Diagnoses in England
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo